KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Bristol Myers Squibb (BMY) Equity Income (2016 - 2024)

Historic Equity Income for Bristol Myers Squibb (BMY) over the last 15 years, with Q3 2024 value amounting to -$23.0 million.

  • Bristol Myers Squibb's Equity Income fell 22777.78% to -$23.0 million in Q3 2024 from the same period last year, while for Sep 2024 it was $12.0 million, marking a year-over-year decrease of 8441.56%. This contributed to the annual value of -$4.0 million for FY2019, which is 10430.11% down from last year.
  • As of Q3 2024, Bristol Myers Squibb's Equity Income stood at -$23.0 million, which was down 22777.78% from $28.0 million recorded in Q2 2024.
  • In the past 5 years, Bristol Myers Squibb's Equity Income registered a high of $40.0 million during Q3 2021, and its lowest value of -$23.0 million during Q3 2024.
  • Its 4-year average for Equity Income is $13.7 million, with a median of $23.0 million in 2023.
  • Over the last 5 years, Bristol Myers Squibb's Equity Income had its largest YoY gain of 35454.55% in 2024, and its largest YoY loss of 22777.78% in 2024.
  • Over the past 4 years, Bristol Myers Squibb's Equity Income (Quarter) stood at $30.0 million in 2020, then skyrocketed by 33.33% to $40.0 million in 2021, then tumbled by 55.0% to $18.0 million in 2023, then tumbled by 227.78% to -$23.0 million in 2024.
  • Its Equity Income stands at -$23.0 million for Q3 2024, versus $28.0 million for Q2 2024 and $18.0 million for Q3 2023.